ADARx Pharmaceuticals, Inc.
ADRXA primary-source company identity page built for fast discovery, filing verification and consistent financial research.
A recent price could not be verified. Check the exchange before trading.
Four checks before any decision
Business model
Understand how the company earns and where demand originates.
Revenue and margin
Compare equivalent periods; separate growth from profitability.
Debt and cash flow
Test balance-sheet resilience and cash conversion.
Valuation and risk
Use sector peers, scenarios and explicit risk limits.
Dates connected to this company
Confirmed events from the FinRatex financial calendar, linked to their named sources.
ADARx Pharmaceuticals IPO Nasdaq trading start
ADARx Pharmaceuticals priced its 26,250,000-share initial public offering at $17.00 per share. The shares were expected to begin trading on the Nasdaq Global Select Market under ADRX on September 25, 2026; the company did not disclose an exact trading-start time. Expected gross proceeds were approximately $446.3 million.
ADARx Pharmaceuticals ↗ADARx Pharmaceuticals IPO closing
ADARx Pharmaceuticals' 26,250,000-share initial public offering is expected to close on September 28, 2026. The price is $17.00 per share and expected gross proceeds are approximately $446.3 million; closing remains subject to customary conditions.
ADARx Pharmaceuticals ↗More NASDAQ records
Alphabetically adjacent directory records for faster navigation; this is not a peer or valuation classification.
Checking SEC financial statements
A dash means standardized data is unavailable. Always check the filing period, currency and accounting scope.